Add prescription telehealth revenue to your med spa

The good faith exam, and who can perform it

Most states expect a good faith exam before a new patient receives a medical aesthetic treatment, performed by a physician, NP or PA.

• RNs, aestheticians and medical assistants generally cannot perform it.
• California's SB 351, effective January 1, 2026, bars RNs from the exam and requires a patient-specific order from a physician, NP or PA.
• Whether an NP can act alone depends on state practice authority: full-practice states allow it; Georgia, Ohio and Tennessee require a protocol or collaborative agreement with a physician.

Telehealth GFEs are allowed in most states, with conditions

As of September 2026, most states permit the good faith exam by synchronous audio-video telehealth.

• Texas and Florida tie telehealth GFEs to delegation and prescribing-authority rules; California permits asynchronous questionnaires in some circumstances.
• The provider must be licensed where the patient is physically located, and the exam must be documented to the in-person standard.
• MyOrbitHealth applies state rules at intake so a patient in a video-only state is never routed to an asynchronous path.

Medical director and the corporate practice of medicine

Every med spa needs a medical director with an active, unrestricted license in the state where the spa operates.

• In most states the corporate practice of medicine doctrine bars a non-physician owner from directing clinical care, so non-physician-owned spas typically pair a management services organization with a physician-owned professional entity.
• Supervision rules vary: Texas requires on-site supervision for lasers, Florida expects the physician to be immediately available, California allows general supervision for delegated injections.
• Your medical director keeps the in-office role; MyOrbitHealth's providers handle telehealth encounters under the managed-services structure, and your counsel confirms how the two fit.

503A take-home versus 503B office stock

A 503A compounding pharmacy fills a patient-specific prescription and ships it to that patient.

• It cannot legally supply a shelf of vials for your treatment room.
• Only an FDA-registered 503B outsourcing facility can compound office stock without a patient-specific prescription, under cGMP and FDA inspection.
• OrbitRx is the 503A and retail path: a provider writes for a named patient and the pharmacy ships to that patient.
• Office stock for in-person administration comes through a 503B or manufacturer channel your medical director sources separately.

GLP-1 programs after the shortage

The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025; the grace periods for compounded copies ended in spring 2025, and in April 2026 the FDA proposed removing all three GLP-1s from the 503B bulks list.

• As of September 2026 a med spa semaglutide program cannot be built on mass-compounded copies.
• It can be built on FDA-approved products and, in narrow cases, on patient-specific compounding where a prescriber documents a legitimate clinical need.
• Your medical director and the pharmacy decide what is defensible; MyOrbitHealth routes what they approve.

Good faith exams by video, on demand

A new patient books on your storefront or at the front desk.

• Orbit Intake collects history, allergies, medications and photos, and routes the patient to an MD, DO, NP or PA licensed in their state for a video exam.
• Providers respond in under six minutes on average during business hours and coverage runs 24 hours, so a walk-in is not turned away.
• The clearance and any patient-specific order land in OrbitOS for your medical director to review.

GLP-1 weight management as a take-home program

Orbit Intake screens for BMI, comorbidities, contraindications and prior GLP-1 use.

A licensed provider reviews the case, orders baseline labs where appropriate, and prescribes through OrbitRx to a LegitScript-certified pharmacy that ships cold chain to the patient. Refills, titration and check-ins run on a subscription cadence inside your app.

Orbit Labs, drawn three ways

A provider orders the panel.

• The patient collects it as a Quest or Labcorp walk-in with an order slip, a Tasso at-home kit shipped and returned by FedEx, or a mobile phlebotomy visit.
• Results route to the ordering provider, who reads them into the plan; the patient sees an interpreted result, not a raw PDF.
• Your storefront can also carry a patient self-order lab catalog.

Provider Network licensed in all 50 states

2,400+ board-certified providers across 38+ specialties, credentialed to NCQA standards with primary-source verification and monthly OIG and SAM screening.

Every prescriber who touches a controlled substance has completed EPCS identity proofing and holds a DEA registration.

OrbitRx with EPCS to 503A and retail pharmacies

Prescriptions leave OrbitRx through Surescripts, with EPCS two-factor sign-off where a controlled substance is involved.

GLP-1 products, hormone therapies, prescription hair and skin products and ancillaries route to a LegitScript-certified 503A compounding or retail pharmacy, with cold chain for injectables. Medication passes through at 0% markup.

Storefront, app, OrbitOS and developer surface

A branded storefront with checkout and subscriptions, a native iOS and Android app for refills, messaging and results, and OrbitOS as the operator console for encounters, orders, lab status and refill queues.

Teams with their own site use the REST API, webhooks and React SDK; a public MCP server lets internal tools query program state. Managed LegitScript certification is included: we prepare, file and manage your brand's application through approval, typically days once filed, with the decision resting with LegitScript.